Risdiplam
FDA-approved product (for solution, oral), marketed as Evrysdi.
- Registered studies
- 33
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Atrophy
- Proximal spinal muscular atrophy
- Spinal muscular atrophy
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other drugs for disorders of the musculo-skeletal system
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli42.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae35.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
33registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Risdiplam with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Nirogacestat HydrobromideExisting use: Gastrointestinal desmoid tumor47.9% AI-predicted activityagainst E. coli1 registered study
- Naratriptan HydrochlorideExisting use: Migraine disorder47.7% AI-predicted activityagainst E. coli4 registered studies
- Tepotinib HydrochlorideExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma47.7% AI-predicted activityagainst E. coli6 registered studies
- Cobimetinib FumarateExisting use: Cancer, Melanoma, Metastatic melanoma and 1 more47.6% AI-predicted activityagainst E. coliNo documented evidence found
- RevefenacinExisting use: Airway obstruction, Chronic obstructive pulmonary disease47.5% AI-predicted activityagainst E. coli20 registered studies
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma47.3% AI-predicted activityagainst E. coli50+ registered studies
- Vincristine SulfateExisting use: Neoplasm47.2% AI-predicted activityagainst E. coli50+ registered studies
- BrexpiprazoleExisting use: Major depressive disorder, Psychosis, Schizoaffective disorder and 1 more47.2% AI-predicted activityagainst E. coli50+ registered studies
- Octreotide AcetateExisting use: Acromegaly, Carcinoid tumor, Metastasis and 1 more47.0% AI-predicted activityagainst E. coli50+ registered studies
- DeserpidineExisting use: Hypertension47.0% AI-predicted activityagainst E. coliNo documented evidence found
- Ioflupane I-123Existing use: Abnormality of movement, Alzheimer disease, Computed tomography and 7 more47.0% AI-predicted activityagainst E. coli36 registered studies
- Montelukast SodiumExisting use: Airway obstruction, Allergic rhinitis, Asthma and 2 more46.9% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) Given by Mouth in Healthy Volunteers
NCT02633709 · start 2016-01-07
Registered record
- Registry ID
- NCT02633709
- Conditions
- Spinal Muscular Atrophy
- Interventions
- Itraconazole; Placebo; Risdiplam
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2016-01-07
- Completion
- 2016-08-04
- Enrolment
- 33
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSpinal Muscular AtrophyInterventionItraconazole; Placebo; RisdiplamPhasePhase 1Registry statusCompletedRegistry Study of Assistive Devices, Medicines and Healthcare Measures in ALS, SMA and Other Neurological Diseases.
NCT05852418 · start 2015-10-30
Registered record
- Registry ID
- NCT05852418
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Recruiting
- Start
- 2015-10-30
- Completion
- 2029-06
- Enrolment
- 25,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAmyotrophic Lateral SclerosisInterventionNot recordedPhaseNot recordedRegistry statusRecruitingAn Expanded Access Program for Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
NCT04256265
Registered record
- Registry ID
- NCT04256265
- Conditions
- Muscular Atrophy, Spinal
- Interventions
- Risdiplam
- Study type
- EXPANDED_ACCESS
- Phase
- Not recorded
- Registry status
- Approved for marketing
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMuscular Atrophy, SpinalInterventionRisdiplamPhaseNot recordedRegistry statusApproved for marketing